2023 World Conference on Lung Cancer (Posters)-P1.23. ctDNA Positivity Is a Clinical Prognosis Biomarker in Patients with EGFR ex20ins+ NSCLC

P1.23. ctDNA Positivity Is a Clinical Prognosis Biomarker in Patients with EGFR ex20ins+ NSCLC - PDF(Abstract)

Pdf Summary

A study presented at the World Conference on Lung Cancer (WCLC) in 2023 explored the use of circulating tumor DNA (ctDNA) as a prognostic biomarker in patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations. The study focused on patients treated with mobocertinib, an oral tyrosine kinase inhibitor. <br /><br />The researchers analyzed plasma samples from 80 patients who had previously received platinum-based chemotherapy and were treated with mobocertinib. The ctDNA detection was measured by the variant allelic fraction (VAF) of EGFR ex20ins mutations in the plasma samples. <br /><br />The results showed that patients who had no EGFR ex20ins ctDNA detected at baseline had a longer median progression-free survival (PFS) of 14.69 months compared to patients with EGFR ex20ins ctDNA detected, who had a median PFS of 5.52 months. Clearance of EGFR ex20ins ctDNA from baseline to Cycle 3, Day 1 was associated with a longer PFS of 10.78 months compared to patients with positive ctDNA status.<br />Furthermore, an increase in ctDNA VAF at Cycle 3, Day 1 was associated with a higher risk of disease progression, while patients who remained negative for ctDNA at both baseline and Cycle 3, Day 1 had a longer PFS.<br /><br />These findings suggest that ctDNA detection and clearance can serve as a clinical prognosis biomarker in patients with EGFR ex20ins NSCLC treated with mobocertinib. The study highlights the potential of ctDNA as a prognostic biomarker in this specific group of patients and calls for further testing and validation of ctDNA as a biomarker for NSCLC.

Asset Subtitle

Sampurna Chatterjee

Meta Tag

Speaker Sampurna Chatterjee

Topic Pathology & Biomarkers: Liquid Based Biomarkers

Keywords

World Conference on Lung Cancer

ctDNA

prognostic biomarker

non-small cell lung cancer

NSCLC

epidermal growth factor receptor

EGFR exon 20 insertion

ex20ins mutations

mobocertinib

oral tyrosine kinase inhibitor